[go: up one dir, main page]

MX9700229A - Vacuna de polinucleotido para virus de papiloma. - Google Patents

Vacuna de polinucleotido para virus de papiloma.

Info

Publication number
MX9700229A
MX9700229A MX9700229A MX9700229A MX9700229A MX 9700229 A MX9700229 A MX 9700229A MX 9700229 A MX9700229 A MX 9700229A MX 9700229 A MX9700229 A MX 9700229A MX 9700229 A MX9700229 A MX 9700229A
Authority
MX
Mexico
Prior art keywords
polynucleotide vaccine
papilloma virus
papiloma
viruses
papiloma viruses
Prior art date
Application number
MX9700229A
Other languages
English (en)
Inventor
John J Donnelly
Margaret A Liu
Douglas Martinez
Donna L Montgomery
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MX9700229A publication Critical patent/MX9700229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Construcciones de ADN que codifican productos de gen de virus de papiloma, capaces de expresarse por introduccion directa hacia tejidos novedosos animales, son agentes farmacéuticos profilácticos novedosos que pueden proveer proteccion inmune contra infeccion por virus de papiloma.
MX9700229A 1994-06-30 1995-06-01 Vacuna de polinucleotido para virus de papiloma. MX9700229A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26842494A 1994-06-30 1994-06-30
PCT/US1995/006915 WO1996000583A1 (en) 1994-06-30 1995-06-01 Polynucleotide vaccine for papillomavirus

Publications (1)

Publication Number Publication Date
MX9700229A true MX9700229A (es) 1997-04-30

Family

ID=23022939

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700229A MX9700229A (es) 1994-06-30 1995-06-01 Vacuna de polinucleotido para virus de papiloma.

Country Status (20)

Country Link
US (1) US5866553A (es)
EP (1) EP0768893B1 (es)
JP (1) JPH10501987A (es)
CN (1) CN1156966A (es)
AT (1) ATE233101T1 (es)
AU (1) AU701973B2 (es)
CA (1) CA2193365C (es)
CZ (1) CZ375296A3 (es)
DE (1) DE69529748T2 (es)
ES (1) ES2191052T3 (es)
FI (1) FI965224L (es)
HU (1) HU220747B1 (es)
IL (1) IL113817A (es)
MX (1) MX9700229A (es)
NO (1) NO965590L (es)
NZ (1) NZ288045A (es)
PL (1) PL180639B1 (es)
SK (1) SK164196A3 (es)
WO (1) WO1996000583A1 (es)
ZA (1) ZA954641B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
EP1017283B1 (en) * 1997-02-14 2004-12-15 Merck & Co., Inc. Polynucleotide vaccine formulations
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
EP1071377A1 (en) * 1998-04-14 2001-01-31 Merck & Co., Inc. Needleless administration of polynucleotide formulations
EP1108035B1 (en) * 1998-09-04 2007-08-08 Sanofi Pasteur Limited Treatment of cervical cancer
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
IL144084A0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
DK1459766T3 (da) * 1999-03-26 2008-10-13 Vical Inc Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
JP4932086B2 (ja) * 1999-04-08 2012-05-16 インターセル ユーエスエイ、インコーポレイテッド 経皮的免疫のための乾燥製剤
AU772611B2 (en) * 1999-08-25 2004-05-06 Merck Sharp & Dohme Corp. Synthetic human papillomavirus genes
US7001995B1 (en) 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
SE0002498D0 (sv) * 2000-07-03 2000-07-03 Stefan Schwartz Papillomavirus vaccine
KR20020005332A (ko) * 2000-07-10 2002-01-17 정상훈 탈모증 치료용 키트
DK1372708T3 (da) * 2001-02-13 2008-10-20 Us Gov Sec Army Vaccine til transkutan immunisering mod rejsediarre
AU2002308713B2 (en) * 2001-06-22 2008-05-15 The Trustees Of The University Of Pennsylvania Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
US20040208848A1 (en) * 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
DE602005021756D1 (de) * 2004-02-13 2010-07-22 Nod Pharmaceuticals Inc Partikel mit kern aus calciumphosphat-nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung
WO2006050368A2 (en) 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles iin use for aesthetic or cosmetic medicine, and methods of manufacture and use
US8404244B2 (en) * 2005-02-01 2013-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
DK2154147T3 (en) * 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
BRPI0815818A2 (pt) 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 truncada do papiloma vírus humano tipo 18
WO2008145021A1 (fr) * 2007-05-29 2008-12-04 Xiamen University Protéine l1 tronquée du papillomavirus humain de type 6
WO2014151279A1 (en) * 2013-03-15 2014-09-25 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-23 as an adjuvant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
WO1986005816A1 (en) * 1985-04-04 1986-10-09 Georgetown University Type-specific papillomavirus dna sequences and peptides
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
ES2200016T3 (es) * 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
DE122007000018I1 (de) * 1991-07-19 2007-05-24 Univ Queensland Polynukleotidabschnitt des HPV16-Genoms
US5376542A (en) * 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
ZA935355B (en) * 1992-08-07 1995-01-23 American Home Prod Recombinant andenovirus vaccines
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization

Also Published As

Publication number Publication date
HU220747B1 (hu) 2002-05-28
AU701973B2 (en) 1999-02-11
NO965590L (no) 1997-02-28
PL317874A1 (en) 1997-04-28
JPH10501987A (ja) 1998-02-24
AU2694595A (en) 1996-01-25
WO1996000583A1 (en) 1996-01-11
ES2191052T3 (es) 2003-09-01
CA2193365A1 (en) 1996-01-11
CZ375296A3 (en) 1997-08-13
CA2193365C (en) 2007-04-03
FI965224A0 (fi) 1996-12-27
HUT76446A (en) 1997-09-29
SK164196A3 (en) 1997-08-06
PL180639B1 (pl) 2001-03-30
DE69529748T2 (de) 2003-10-16
FI965224A7 (fi) 1996-12-27
NZ288045A (en) 1998-08-26
IL113817A (en) 2001-03-19
FI965224L (fi) 1996-12-27
DE69529748D1 (de) 2003-04-03
EP0768893B1 (en) 2003-02-26
EP0768893A1 (en) 1997-04-23
ATE233101T1 (de) 2003-03-15
US5866553A (en) 1999-02-02
CN1156966A (zh) 1997-08-13
ZA954641B (en) 1996-01-26
IL113817A0 (en) 1995-08-31
HU9603562D0 (en) 1997-02-28
NO965590D0 (no) 1996-12-27

Similar Documents

Publication Publication Date Title
MX9700229A (es) Vacuna de polinucleotido para virus de papiloma.
GR3035458T3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
ATE453403T1 (de) Wirtszelle enthaltend ein rekombinantes virus, welches ein antigen exprimiert und ein rekombinantes virus, welches ein immunstimulatorisches molekül exprimiert
TR200001835T2 (tr) Aşı.
WO1996011279A3 (en) Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
HUP9901112A2 (hu) Szintetikus HIV-gének
LU93259I2 (fr) LETIFEND (Protein Q)
ATE228016T1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
ATE285239T1 (de) Dna enthaltende impfstoffen
EP0868522A4 (en) RECOMBINANT POX VIRUS OF INFECTIOUS PERITONITIS OF THE CAT, COMPOSITIONS THEREOF AND METHODS FOR THE PRODUCTION AND USE
EA200100700A1 (ru) Гены и белки и их применение
ES2058100T3 (es) Vacuna combinada.
ES2177535T3 (es) Vacunas contra protozoos intestinales.
IL148741A0 (en) Vaccine
ES2146574T3 (es) Secuencias de nucleotidos y polipeptidos, en particular del virus del colera del cerdo.
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
NO20013101L (no) Ytre overflateproteiner, deres gener og deres anvendelse
BR9801992A (pt) Processos para a preparação de vìrus da doença de marek usando linhas celulares contìnuas de mamìfero.
MX9709347A (es) Micoplasma synoviae no virulento y vacuna del mismo.
MX9708615A (es) Terapia de genes animales.